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Summary: 
Tuberous sclerosis complex (TSC) is a multisystem genetic disorder caused by mutations in TSC1 or 
TSC2. Epilepsy occurs in 80 to 90% of affected individuals during their lifetime, and up to one third 
of children with TSC will develop epileptic (infantile) spasms, for which vigabatrin has been shown 
to be particularly effective. Epilepsy severity and epileptic spasms are consistent markers of risk for 
the development of intellectual impairment in TSC. While previous studies demonstrate a bimodal 
distribution of intellectual ability in TSC, recent findings suggest a unimodal distribution, which may 
reflect a change in IQ distribution over time. We compared three large historical UK cohorts of TSC 
(n=331) that show varied distributions of intellectual ability, first ruling out differences in study 
methodology. Later-born individuals had a higher frequency of reported spasms and higher 
likelihood of vigabatrin administration, but were less likely to have profound intellectual 
impairment, compared to the earlier-born individuals. Our findings suggest that epileptic spasms 
went undetected in the older patients and therefore were not treated, leading to a higher 
occurrence of profound impairment, whereas the later born cohort had better access to treatment. 
These findings support the importance of early identification and treatment of seizures in TSC. 
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Introduction 
Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by a mutation of TSC1 or TSC2 
and characterized by the multisystemic growth of tumour-like lesions called hamartomas. Cortical 
tubers or perituberal cortex act as epileptogenic foci during the early postnatal period and are 
associated with an increased risk of epilepsy, intellectual impairment and behavioural disturbances. 
Approximately 90% of individuals with TSC will develop epilepsy, with seizures usually beginning in 
the first year of life1. Epileptic (infantile) spasms are observed in around half of all cases, associated 
with developmental regression and intractable epilepsy2. 
 
Approximately 50% of individuals develop an intellectual disability, which can range from mild to 
profound3. Epilepsy severity and epileptic spasms are a consistent marker of risk for the 
development of intellectual impairment in TSC. Prospective longitudinal studies indicate poor 
intellectual development in the first two years of life in infants with spasms4, and a clear impairment 
in the development of IQ after the onset of spasms has been demonstrated compared to non-spasm 
seizures5. The risk of epileptic spasms is correlated with the number of cortical tubers and the 
presence of TSC2 versus TSC1 mutations, and contributes to increased epilepsy severity. In line with 
this, recent findings suggest a cascading risk pathway from type of genetic mutation, to cortical 
tuber ‘load’, to epilepsy severity, through to intellectual ability6. 
 
Several studies demonstrate a bimodal distribution of intellectual ability in TSC. This indicates that 
most individuals with TSC fall either into the normal ability range or profoundly impaired range of 
intellectual ability, and therefore that distinct subgroups may exist, for example, based on type of 
genetic mutation7-9. Recent findings, however, suggest a change to a unimodal distribution in the 
UK6. The reason for the change in distribution is unclear and could reflect methodological 
differences between cohorts, a decline in IQ in a subset of cases reflecting developmental change, 
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or a true change in IQ distribution over time. We sought to address this question by directly 
comparing the characteristics of three large independent cohorts of individuals with TSC. 
  
Methods 
We directly compare and combine findings from three cohorts of TSC:  
(1) the Wessex cohort (n=108, DoB: 1922–1995, age=4.0-75.0 years, M:F=1:0.9) was ascertained 
through a 1998 census in the Wessex area of SW England10. The average reported age at seizure 
onset was 28.6 months and 47% of the sample had a history of epileptic spasms. Data was not 
available for the proportion that received vigabatrin treatment. Assessment of intellectual 
ability was conducted using the Wechsler Adult Intelligence Scale (WAIS-R), Wechsler 
Intelligence Scale for Children (WISC-III), Raven’s Coloured Progressive Matrices, or Vineland 
Adaptive Behaviour Scale. The median IQ was 75. Estimated IQ was bimodally distributed, with 
a skewness of -0.14 and a kurtosis of -1.51. 55.5% had IQ in the normal range, 14% had mild to 
severe impairments, and 30.5% had profound disability. 
(2) the Cardiff cohort (n=98; DoB=1930–1995, age=6.0-70.0 years, M:F=1:0.9), ascertained for 
molecular genetic research through adult and pediatric medical clinics, regional genetics 
services and learning disability services8. The average reported age of seizure onset was 43.3 
months and 44% of the sample had a history of epileptic spasms, with 20% of the sample 
administered vigabatrin. Assessment of intellectual level was conducted using the Wechsler 
Adult Intelligence Scale (WAIS-R), Wechsler Intelligence Scale for Children (WISC-III), Raven’s 
Coloured Progressive matrices, or Vineland Adaptive Behaviour Scale. The median IQ was 65. 
Estimated IQ was bimodally distributed with a skewness of 0.09 and a kurtosis of -1.63. 47.5% 
had IQ in the normal range, 20.5% had mild to severe impairments and 32% had profound 
disability. 
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(3) the TS 2000 cohort (n=125, DoB=1986–2005, age=0.3-21.2 years, M:F=1:0.9) a prospective 
longitudinal study of children in the UK aged 0-16 years newly diagnosed with TSC between 
January 2001 and December 20056; 11. The average age at seizure onset was 13.5 months and 
49% of the sample had a history of epileptic spasms, with 51% of the sample being administered 
vigabatrin. Assessment of intellectual level was conducted using the Mullen Scales of Infant 
Development and the Vineland Adaptive Behaviour Scales. The median IQ was 64. Estimated IQ 
was unimodally distributed, with a skewness of 0.83 and a kurtosis of 0.54. 34.5% had IQ in the 
normal range, 61.5% had mild to severe impairments, and 1% had profound disability. 
 
Findings 
Although there were some differences in the modes of ascertainment between the three studies 
(e.g. the TS 2000 Study recruited all newly diagnosed children with TSC over a set period of time, 
whereas the Wessex sample included all cases known to Wessex services, as well as secondarily 
ascertained cases), these differences cannot explain the differences observed in IQ distribution 
across cohorts. Also, comparable standardized approaches to estimating IQ were utilised. 
Moreover, there were no differences in the sex ratio (x2=0.01, p=.99), history of epileptic spasms 
(x2=0.34, p=.84), or age at seizure onset (H (2) = 2.02, p=.37) by cohort.  When considered as a whole, 
there was no significant difference in IQ between studies (F (1, 324) = 1.98, p=.14). When 
considering rates of intellectual disability (normal >70; mild to moderate 35-70; severe to profound 
<20-35), significantly fewer individuals in the TS 2000 cohort had severe to profound disability and 
more had mild to moderate disability, compared to the Wessex and Cardiff cohorts (x2=89.91, 
p<.001). Within the subset of individuals with severe to profound disability, there was no significant 
difference across cohorts by sex, reported age of seizure onset, history of spasms or type of 
mutation (TSC1 versus TSC2; all p>.05). 
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A regression of IQ on date of birth (beta = -0.03, p=.60) and age (beta=0.04, p=.44), revealed neither 
were significant predictors of IQ. The cohort to which the participant belonged to did not 
significantly predict IQ on it’s own (beta=-0.07, p=.22) or when entered with age (beta=-0.06, p=.26), 
and date of birth (beta= -0.07, p=.23), suggesting differences in IQ are not the result of cohort 
effects.  
 
Distribution of genetic mutations across cohorts 
Differences in the distribution of IQ may reflect differences in the type and location of the genetic 
mutation across the cohorts. Germline mutations were known for 94 participants from TS 2000 (75 
patients had TSC2 mutations and 19 had TSC1) and 83 from the Cardiff cohort (70 with TSC2 
mutations and 13 with TSC1). Germline mutations were unavailable from the Wessex cohort. There 
was no difference in the frequency of TSC1 versus TSC2 mutations between the London and Cardiff 
cohorts (x2=0.47, p=.49). There was no difference in the rate of TSC1 or TSC2 missense mutations, 
mutations in the TSC1 tuberin interaction domain, mutations in the TSC2 hamartin binding domain, 
TSC2 mutations in the GAP domain, protein truncating TSC2 mutations or proximal protein 
truncating TSC2 mutations (see Supplementary Materials). 
 
Changes in epilepsy management 
An alternative explanation for the change in IQ distribution is improvement in the management of 
epilepsy, and in particular epileptic spasms, in the last two decades. The primary approved 
treatments for children with epileptic spasms are steroid therapy and vigabatrin. Corticosteroids 
were introduced in the late 1940’s whereas vigabatrin was approved in 1995. In line with this, 
significantly more individuals in the TS 2000 cohort received vigabatrin treatment compared to the 
Cardiff cohort (x2=22.67, p<.001). To explore this question further, we combined data from all three 
cohorts and stratified by date of birth (before 1950, 1950-1995, and after 1995). There was a higher 
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rate of vigabatrin treatment (x2=23.72, p<.001; Cardiff and TS 2000) and history of epileptic spasms 
in those born after 1995 (x2=7.72, p=.02; all three cohorts). 
 
If epileptic spasms are a risk factor for intellectual impairment, and their effective treatment leads 
to less severe disability, we might expect there to be a difference between cohorts for those that 
have epileptic spasms only, as the TS 2000 cohort had better access to treatment. Consistent with 
this, there were significant differences in IQ by cohort (F (2,150)=14.76, p<.001) for these 
individuals; those in the TS 2000 study had significantly higher mean IQ (61) compared to those in 
the Wessex (39; p<.001) and Cardiff (42; p<.001) cohorts. 
 
<FIGURE 1 HERE> 
 
In order to exclude the possibility that these differences reflected differences in the age of 
participants at assessment, we matched the individuals from the Wessex and Cardiff samples by age 
to the TS 2000 cohort (range 25 years, n=90). Significant differences in IQ by cohort in individuals 
with a history of spasms were retained between TS 2000 (59), Wessex (43, p=.02) and Cardiff (45, 
p=.04). 
 
Discussion 
The findings of the current study suggest that while later-born individuals with TSC had a higher 
reported frequency of epileptic spasms, this group were less likely to have profound intellectual 
impairment. In contrast, those born earlier were less likely to have epileptic spasms recorded, more 
likely to have profound intellectual impairment and less likely to have been administered vigabatrin. 
These observations are consistent with a model in which epileptic spasms went undetected or were 
detected late in the older patients and therefore were not treated promptly and/or effectively, 
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leading to a higher occurrence of profound impairment (and therefore a bimodal distribution of IQ 
in TSC).  
 
This hypothesis must be directly tested. For example, it can be postulated that in countries where 
vigabatrin is not yet available a bimodal distribution would still be observed. In addition, the 
possibility that there may be intellectual decline later in development cannot be ruled out. Declines 
in IQ have been reported in subsets of infants 12 and children with TSC 13, but intellectual ability 
appears to be stable in the majority of individuals after early childhood. Future analyses of 
longitudinal cohorts into adulthood are important to reveal whether such subgroups emerge with 
development and what processes are related to these changes.  
 
While detection and treatment of epileptic spasms may be important in determining risk for severe 
to profound intellectual impairment, other risk factors should not be overlooked. History of epileptic 
spasms is consistently linked to lower intelligence in univariate analyses, yet multifactorial analyses 
that are able to test the joint effects of several influencing factors have suggested that age at seizure 
onset is the sole variable to independently predict intellectual outcome4; 14; 15, thus other types of 
epilepsy, including focal seizures, occurring early in life necessitate prompt management16; 17. It is 
likely that intellectual development in TSC is determined by a complex and dynamic interaction 
between several risk factors, including number, location and relative proportion of cortical tubers 
and type of genetic mutation in addition to certain features indexing epilepsy severity.6; 14  
 
These findings have implications for the identification and prevention of the epilepsy-related risk 
factors that are involved in shaping intellectual development in TSC. This proposition is timely given 
recent advances in our understanding of the pathophysiology and treatment of early-onset epilepsy 
in TSC. Clinical seizures are preceded by abnormalities on EEG recordings and preventative 
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treatment of epileptiform discharges may affect the evolution to clinically evident subtle partial 
seizures and spasms, which may be difficult for parents to identify18; 19. For example, infants treated 
with vigabatrin based on identification of paroxysmal activity on EEG before the onset of clinical 
seizures had better cognitive outcome at 24 months of age, compared to those treated post-seizure 
onset20, work which is being continued within the EPISTOP project (www.epistop.eu). In addition, 
patients diagnosed with TSC pre-seizure onset have a lower prevalence of refractory seizures and 
severe developmental disability, compared to those diagnosed post-seizure onset, despite no 
regular surveillance EEG21.  
 
Several clinical trials are ongoing focused on neurocognitive outcome in TSC based on identified risk 
factors, for example, using mTOR inhibitors that target the downstream effect of the primary 
mutation (ClinicalTrials.gov Identifier: NCT01289912), through to parent-based intervention 
(NCT03422367), and identification of EEG biomarkers of early versus delayed vigabatrin 
treatment in infants with TSC (NCT02849457). The results of these large-scale longitudinal and 
interventional studies of TSC are eagerly awaited. Future work that systematically measures the 
separate and combined effects of candidate risk factors in neurocognitive development are 
required, in order to guide routine surveillance and treatment strategies and improve longer-term 
outcome in TSC. 
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Figure 1: Distribution of intellectual ability by year of birth across all cohorts: a) 1922-1950; b) 
1950-1995, introduction of corticosteroids; c) 1995 onwards, introduction of vigabatrin 
 
